New vaccine booster aims to shield against many coronaviruses
NCT ID NCT07113106
First seen Apr 15, 2026 · Last updated Jun 19, 2026 · Updated 10 times
Summary
This study tests a new booster vaccine called CD40.Pan.CoV in 48 healthy adults in France. The goal is to see if it is safe and can boost the body's defenses against multiple coronavirus variants. Participants receive one injection and are monitored for side effects and immune response for one month.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CIC 1403 CHU de Lille
Lille, 59037, France
-
CIC 1405 CHU Clermont Ferrand
Clermont-Ferrand, 63000, France
-
CIC 1413 CHU de Nantes
Nantes, 44093, France
-
CIC 1417 Cochin-Pasteur Hôpital Cochin
Paris, 75014, France
-
CIC 1427 Hôpital St Louis
Paris, 75475, France
-
Centre de Recherche Clinique CHU de Caen Normandie
Caen, 14033, France
-
Hôpital Henri Mondor
Créteil, 94010, France
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.